Literature DB >> 15618359

Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.

Xin-Hua Liu1, Alexander Kirschenbaum, Shen Yao, Alice C Levine.   

Abstract

The osteoprotegerin (OPG)/receptor activator of nuclear factor-kappaB ligand (RANKL)/receptor activator of nuclear factor-kappaB (RANK) system is the dominant and final mediator of osteoclastogenesis. Abnormalities of this system have been implicated in the pathogenesis of many skeletal diseases. Cyclooxygenase (COX)-2 and prostaglandin (PG)E(2), a major eicosanoid product of the COX-2-catalyzed pathway, play key roles in normal bone tissue remodeling. PGE(2) exerts its actions by binding and activating the E series of prostaglandin (EP) receptor. Activation of EP(2) and EP(4) receptors is associated with PGE(2)-induced osteoclast differentiation. IL-6, a major proinflammatory cytokine, has also been reported to induce osteoclast differentiation. Although interactions between the COX-2/PGE(2) and IL-6 systems have been described in bone cells, the mechanisms underlying these cooperative signaling pathways and the possible involvement of the OPG/RANKL/RANK system have not been fully elucidated. We demonstrate that COX-2, PGE(2), and IL-6 stimulate osteoblast growth and osteoclast differentiation. Effects on osteoclast differentiation, particularly with IL-6, were most marked when osteoclast precursor cells were grown in coculture with osteoblasts, indicating a possible role of the RANK/RANKL/OPG system. COX-2 and PGE(2) stimulated osteoclastogenesis through inhibition of OPG secretion, stimulation of RANKL production by osteoblasts, and up-regulation of RANK expression in osteoclasts. PGE(2) stimulated IL-6 secretion by bone cells, whereas COX-2 inhibitors decreased this same parameter. IL-6, in turn, increased PGE(2) secretion, COX-2, and EP receptor subtype expression in bone cells. Finally, IL-6 was the mediator of PGE(2)-induced suppression of OPG production by osteoblasts. These findings provide evidence for cross-talk between the PGE(2) and IL-6 signaling enhance osteoclast differentiation via effects on the OPG/RANKL/RANK system in bone cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15618359     DOI: 10.1210/en.2004-1167

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  64 in total

Review 1.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

2.  Up-regulation of the inflammatory response by ovariectomy in collagen-induced arthritis. effects of tin protoporphyrin IX.

Authors:  Lidia Ibáñez; Maria José Alcaraz; Nuria Maicas; David Guede; José Ramón Caeiro; Marije I Koenders; Wim B van den Berg; Maria Luisa Ferrándiz
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

Review 3.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

4.  An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption.

Authors:  B S Herrera; T Ohira; L Gao; K Omori; R Yang; M Zhu; M N Muscara; C N Serhan; T E Van Dyke; R Gyurko
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

5.  Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts.

Authors:  D Hormdee; T Nagasawa; M Kiji; R Yashiro; H Kobayashi; G Koshy; K Noguchi; H Nitta; I Ishikawa
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 6.  Subchondral bone and osteoarthritis: biological and cellular aspects.

Authors:  Y Henrotin; L Pesesse; C Sanchez
Journal:  Osteoporos Int       Date:  2012-11-22       Impact factor: 4.507

7.  Closing the gap between viral and noninfectious arthritis.

Authors:  Kate D Ryman; William B Klimstra
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

Review 8.  Impact of inflammation on the osteoblast in rheumatic diseases.

Authors:  Rebecca Baum; Ellen M Gravallese
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

Review 9.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

Review 10.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.